[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-269289-105":59,"doc-detail-269289-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","northstar-response-results-report-v250","Northstar Response 结果报告 - V2.5.0","","Northstar Response Results report details a next-generation sequencing (NGS) assay measuring changes in methylated tumor molecules in a patient blood draw over time. It records a detected decrease in Tumor Methylation Score™ versus the previous collection, implying a reduced tumor fraction compared with earlier measurements. The document explains what the score represents across >500 hypermethylated ctDNA loci, how methylation from buffy coat is subtracted to remove background, and the key methods, limitations, and interpretation considerations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/northstar-response-results-report-v250/269289/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/northstar-response-results-report-v250/269289.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-15",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"本次检测的核心结论是什么？","Question",{"text":112,"@type":113},"报告检测到 Tumor Methylation Score™ 的下降，基于甲基化 ctDNA 分子数量减少。该变化提示相较于上次检测，肿瘤分数可能降低。","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Tumor Methylation Score™ 表示什么？",{"text":117,"@type":113},"Tumor Methylation Score™ 表示在循环肿瘤 DNA（ctDNA）中于 >500 个位点的甲基化分子归一化汇总，这些位点在肿瘤中呈高甲基化。",{"name":119,"@type":110,"acceptedAnswer":120},"哪些情况可能影响结果有效性或导致无法报告？",{"text":121,"@type":113},"当样本 cfDNA 含量不足时可能不报告甲基化结果；检测低于可量化范围时不做解释性结论。若患者近期发生输血、干细胞移植或其他可能显著改变 cfDNA 组成的操作，结果可能无效或偏差。","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},269289,1789450010,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":14,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":129,"read_time":24},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","RESPONSE  \nT 833.537.1819  \nF 833.874.0918  \n[E](E support@northstaronc.com)[ support@northstaronc.com](E support@northstaronc.com)  \n[northstaronc.com](northstaronc.com)  \nPatient  \nName  \nDate of Birth (Age) Assigned Sex at Birth Diagnosis  \nMedical Record \\# Internal Patient ID  \nPatient Doe 09/02/1947 (75 yrs) Female  \nNon-Small Cell Lung Carcinoma MRN12345  \nID12345  \nSample  \nSpecimen Type Collection Date Receipt Date Accession ID Report Date Test Number  \nBlood 01/01/2023  \n01/02/2023 VEE0121700003 02/12/2024  \n2  \nPhysician  \nOrdering Physician Medical Facility Address  \nPhone Fax  \nDr. Jane Smith  \nUC San Diego Health 3855 Health Sciences Drive La Jolla, CA 92037  \n(858) 822-6100  \n(858) 822-6100  \nNorthstar Response Results  \n􀀁  \nDECREASE in Tumor Methylation Score™ was detected based on a decrease in methylated ctDNA molecules.  \n94-fold 􀀁  \nFold-change in Tumor Methylation Score™ detected since the previous collection date on 10/03/2022 .  \nTumor Methylation Score™ Represents the normalized sum of methylated molecules at >500 loci that are hypermethylated in circulating tumor DNA (ctDNA) .  \nInterpretation  \nA decrease in methylated, circulating tumor DNA (ctDNA) molecules was detected compared to the previous measurement. This result suggests that tumor fraction has decreased compared to the previous measurement. Compared to normal methylation patterns in the DNA of healthy cells, there are distinct and differential methylation patterns associated with cancer cells [1], and changes in quantity of methylated ctDNA corresponds to a change in the patient’s tumor fraction [3] .  \nBillionToOne, Inc. 1035 O’Brien Drive, Menlo Park, CA 94025 CLIA \\#: 05D2275351. CLF-90008579. Lab Director: Joseph Michael Anderson, MD Version: 2.5.0-8ef2d02 Page 1 of 2  \nRESPONSE  \nT 833.537.1819  \nF 833.874.0918  \n[E](E support@northstaronc.com)[ support@northstaronc.com](E support@northstaronc.com)  \n[northstaronc.com](northstaronc.com)  \nPatient Name Diagnosis  \nPatient Doe  \nNon-Small Cell Lung Carcinoma  \nDate of Birth (Age) 09/02/1947 (75 yrs) Internal Patient ID ID12345  \nAssigned Sex at Birth Report Date  \nFemale 02/12/2024  \nMethods and Limitations  \nNorthstar Response™ is a next generation sequencing (NGS)-based test designed to measure the change in methylated tumor molecules in a cancer patient from a blood draw. In particular, Northstar Response™ quantifies the methylated ctDNA (circulating-tumor DNA) molecules isolated from cell-free DNA (cfDNA) at loci known to be hypermethylated in tumors compared to healthy tissue.  \nPlasma and buffy coat were isolated from whole blood collected in a Streck cell-free DNA tube. Cell-free DNA (cfDNA) was extracted from the plasma, and genomic DNA (gDNA) was extracted from the buffy coat. The number of methylated molecules was quantified in both cfDNA and gDNA using BillionToOne’s QCT molecular counting technology [2] at >500 locations in the genome known to be hypermethylated in cancer compared to non-cancerous tissue and blood. Methylation measured in gDNA is subtracted from cfDNA methylation in order to remove background from the ctDNA signal. The remaining cfDNA methylated molecules are summed across all hypermethylation locations to calculate the Tumor Methylation Score™ [3] .  \nThe Tumor Methylation Score™ from the current collection was compared to the most recently reported Tumor Methylation Score™ to determine an increase, decrease, or no change call. The change in Tumor Methylation Score™ must exceed an analytical, statistical significance threshold in order to be reported as an increase or a decrease. No interpretive calls for change in Tumor Methylation Score™ are made for baseline tests without any prior collections. Results should be discussed with a medical professional and interpreted in conjunction with the patient's complete clinical history within the context of multiple timepoints. The Tumor Methylation Score™ is highly dependent on tumor shedding patterns, which are infl","cbCaimbe54v5H8ob","https://ap.wps.com/l/cbCaimbe54v5H8ob","pdf",181568,"English","# Patient information\n## Diagnosis and sample details\n# Northstar Response results\n## Tumor Methylation Score interpretation\n# Methods and limitations\n## Assay workflow and reporting rules\n## Conditions affecting validity","[{\"question\":\"本次检测的核心结论是什么？\",\"answer\":\"报告检测到 Tumor Methylation Score™ 的下降，基于甲基化 ctDNA 分子数量减少。该变化提示相较于上次检测，肿瘤分数可能降低。\"},{\"question\":\"Tumor Methylation Score™ 表示什么？\",\"answer\":\"Tumor Methylation Score™ 表示在循环肿瘤 DNA（ctDNA）中于 \\u003e500 个位点的甲基化分子归一化汇总，这些位点在肿瘤中呈高甲基化。\"},{\"question\":\"哪些情况可能影响结果有效性或导致无法报告？\",\"answer\":\"当样本 cfDNA 含量不足时可能不报告甲基化结果；检测低于可量化范围时不做解释性结论。若患者近期发生输血、干细胞移植或其他可能显著改变 cfDNA 组成的操作，结果可能无效或偏差。\"}]","Northstar Response 结果报告 - V2.5.0 | PDF"]